News & Updates

Show Multimedia Only

Original New Drug Application Approvals by US FDA (1-15 October 2024)

22 Oct 2024

New drug applications approved by US FDA as of 1-15 October 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 October 2024)

22 Oct 2024

Original New Drug Application Approvals by US FDA (16-30 September 2024)

21 Oct 2024

New drug applications approved by US FDA as of 16-30 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 September 2024)

21 Oct 2024

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

19 Oct 2024

EP-104IAR, a diffusion-based long-acting formulation of fluticasone propionate for intra-articular injection, appears to produce meaningful reductions in knee osteoarthritis (OA) pain that last up to 14 weeks, according to data from a phase II SPRINGBOARD study.

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

19 Oct 2024

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

16 Oct 2024

In the treatment of patients with active psoriatic arthritis (PsA), intravenous secukinumab appears to yield rapid and sustained improvements in clinical measures, with a safety profile consistent with that of the subcutaneous formulation, according to the phase III INVIGORATE-2 study.

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

16 Oct 2024

Original New Drug Application Approvals by US FDA (1-15 September 2024)

09 Oct 2024

New drug applications approved by US FDA as of 1-15 September 2024 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 September 2024)

09 Oct 2024

Long-term muscle relaxant benefits limited for certain conditions

08 Oct 2024

The long-term use of skeletal muscle relaxants (SMRs) for chronic pain is beneficial only in patients with painful spasms or cramps and neck pain but not in those with low back pain, fibromyalgia, and headaches, according to the results of a systematic review and meta-analysis.

Long-term muscle relaxant benefits limited for certain conditions

08 Oct 2024

Which factors predict pregnancy outcomes in SLE?

07 Oct 2024

In women with systemic lupus erythematosus (SLE), factors such as disease activity prior to and during conception as well as the presence of secondary antiphospholipid syndrome convey heightened risk of adverse pregnancy outcomes, according to the results of a systematic review and meta-analysis.

Which factors predict pregnancy outcomes in SLE?

07 Oct 2024

RMD patients prioritize info on symptoms, test results in smartphone apps

28 Sep 2024 by

Among the many educational topics and functions available in a smartphone app, the ones considered most important by patients with rheumatic and musculoskeletal diseases (RMD) include symptom monitoring and information about laboratory test results, medications, and disease, reports a study.

RMD patients prioritize info on symptoms, test results in smartphone apps

28 Sep 2024

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

19 Sep 2024 by

Advanced age, chronic comorbidity, and immunodeficiency are established risk factors for herpes zoster (HZ). HZ is a debilitating condition that poses a significant burden on patients’ quality of life and the economy and has a bidirectional relationship with cardiovascular disease (CVD). At the 28^th Hong Kong Medical Forum (HKMF), Professor Kai-Hang Yiu of the Department of Medicine, University of Hong Kong, presented an overview of the public health impact of HZ in high-risk patients with immunocompromised conditions or chronic diseases and discussed the long-term effectiveness of adjuvanted recombinant zoster vaccine (RZV) against HZ.

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

19 Sep 2024

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

19 Sep 2024 by

A 39-year-old female hospital porter presented with dyspnoea and Raynaud’s phenomenon in 2010, with no evidence of sclerodactyly. She tested positive for anti-ribonucleoprotein (anti-RNP) and anti–Scl-70 autoantibodies. High-resolution CT (HRCT) of the chest revealed bilateral ground-glass opacities, suggesting interstitial thickening or fibrosis. Echocardiography showed an elevated estimated right ventricular systolic pressure (RVSP) of 74 mm Hg. These findings, along with other defining features, supported a diagnosis of mixed connective tissue disease (MCTD), complicated by interstitial lung disease (ILD) and possibly pulmonary arterial hypertension (PAH).¹

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

19 Sep 2024

News & Updates

Filter by Specialty:

Specialty:

Original New Drug Application Approvals by US FDA (1-15 October 2024)

Original New Drug Application Approvals by US FDA (1-15 October 2024)

Original New Drug Application Approvals by US FDA (16-30 September 2024)

Original New Drug Application Approvals by US FDA (16-30 September 2024)

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

Diffusion-based extended-release fluticasone propionate helps alleviate knee OA pain

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

Secukinumab infusion shows therapeutic potential in psoriatic arthritis

Original New Drug Application Approvals by US FDA (1-15 September 2024)

Original New Drug Application Approvals by US FDA (1-15 September 2024)

Long-term muscle relaxant benefits limited for certain conditions

Long-term muscle relaxant benefits limited for certain conditions

Which factors predict pregnancy outcomes in SLE?

Which factors predict pregnancy outcomes in SLE?

RMD patients prioritize info on symptoms, test results in smartphone apps

RMD patients prioritize info on symptoms, test results in smartphone apps

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

Prioritizing herpes zoster prevention in patients with chronic diseases or immune-compromised conditions

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH

Early use of an endothelin receptor antagonist in a patient with scleroderma-spectrum connective tissue disease–associated PAH